Raiffeisen Bank International AG Takes $1.13 Million Position in BioNTech SE (NASDAQ:BNTX)

Raiffeisen Bank International AG acquired a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,000 shares of the company's stock, valued at approximately $1,126,000.

Other institutional investors have also modified their holdings of the company. OMERS ADMINISTRATION Corp bought a new stake in shares of BioNTech during the 4th quarter worth approximately $1,014,000. Integral Health Asset Management LLC lifted its stake in shares of BioNTech by 100.0% during the 4th quarter. Integral Health Asset Management LLC now owns 100,000 shares of the company's stock worth $11,395,000 after acquiring an additional 50,000 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of BioNTech during the 4th quarter worth approximately $570,000. Deutsche Bank AG lifted its stake in shares of BioNTech by 2.3% during the 4th quarter. Deutsche Bank AG now owns 304,500 shares of the company's stock worth $34,698,000 after acquiring an additional 6,749 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after acquiring an additional 433,388 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BNTX shares. Citigroup reissued a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $134.00 price objective (down from $145.00) on shares of BioNTech in a report on Wednesday, May 14th. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Morgan Stanley reduced their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $142.08.

BioNTech Stock Up 4.0%

BNTX stock traded up $3.92 on Tuesday, hitting $101.72. 1,812,605 shares of the company's stock were exchanged, compared to its average volume of 937,789. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a 50 day moving average price of $97.36 and a two-hundred day moving average price of $108.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market cap of $24.45 billion, a P/E ratio of -48.44 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The firm's revenue was down 19.5% compared to the same quarter last year. As a group, equities research analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.